Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc. is delisted from the Nasdaq Capital Market due to rule violations regarding private placement transactions. The delisting, involving the issuance of convertible preferred stock and warrants, led to the suspension of trading. While disappointed, the company is exploring alternative markets, remains focused on its clinical development plans for LP-10 and LP-310, and is pressing forward with its mission to address unmet medical needs.